Testing a new drug for autoimmune diseases
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have an autoimmune disease (a condition where your immune system attacks your own body).
- If you are a woman who could become pregnant, you must agree to use birth control and not breastfeed during the study.
- If you are a man, you must agree to use a barrier method of birth control during the study.
- You cannot have had a major organ transplant or stem cell transplant.
- You cannot have severe lung disease that requires oxygen support.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.